Burling Wealth Partners LLC decreased its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 14.9% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 23,011 shares of the company's stock after selling 4,015 shares during the period. Burling Wealth Partners LLC's holdings in Johnson & Johnson were worth $3,816,000 at the end of the most recent reporting period.
Several other large investors have also modified their holdings of the stock. WealthTrak Capital Management LLC acquired a new stake in shares of Johnson & Johnson in the 4th quarter worth $26,000. Mountain Hill Investment Partners Corp. purchased a new stake in shares of Johnson & Johnson in the fourth quarter valued at about $29,000. Conquis Financial LLC purchased a new stake in shares of Johnson & Johnson in the fourth quarter valued at about $33,000. Bernard Wealth Management Corp. purchased a new stake in shares of Johnson & Johnson during the fourth quarter worth about $36,000. Finally, Runnymede Capital Advisors Inc. purchased a new stake in shares of Johnson & Johnson during the fourth quarter worth about $38,000. Institutional investors and hedge funds own 69.55% of the company's stock.
Johnson & Johnson Price Performance
JNJ traded up $0.67 on Friday, reaching $163.65. The company had a trading volume of 9,764,459 shares, compared to its average volume of 8,138,164. The company has a fifty day moving average of $154.10 and a 200-day moving average of $154.84. The company has a market capitalization of $393.75 billion, a P/E ratio of 17.50, a PEG ratio of 2.18 and a beta of 0.41. The company has a current ratio of 1.26, a quick ratio of 1.03 and a debt-to-equity ratio of 0.49. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 33.07%. The company had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. During the same period in the prior year, the company earned $2.82 EPS. Johnson & Johnson's revenue was up 5.8% on a year-over-year basis. As a group, equities research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.
Johnson & Johnson Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be paid a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 3.18%. The ex-dividend date is Tuesday, August 26th. Johnson & Johnson's dividend payout ratio is presently 55.61%.
Wall Street Analyst Weigh In
Several brokerages recently commented on JNJ. Guggenheim upped their price target on shares of Johnson & Johnson from $164.00 to $167.00 and gave the stock a "neutral" rating in a research report on Thursday. Morgan Stanley boosted their target price on shares of Johnson & Johnson from $171.00 to $176.00 and gave the stock an "equal weight" rating in a research report on Thursday. Benchmark raised shares of Johnson & Johnson to a "strong-buy" rating in a report on Thursday, April 24th. Bank of America raised their price objective on shares of Johnson & Johnson from $161.00 to $175.00 and gave the stock a "neutral" rating in a report on Thursday. Finally, The Goldman Sachs Group upgraded shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and boosted their target price for the company from $157.00 to $172.00 in a research note on Wednesday, April 9th. Eleven investment analysts have rated the stock with a hold rating, nine have issued a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat.com, Johnson & Johnson has an average rating of "Moderate Buy" and an average price target of $174.11.
Check Out Our Latest Report on Johnson & Johnson
Johnson & Johnson Profile
(
Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Further Reading
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
